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ABSTRACT 
 
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the progressive 
deterioration of memory and other intellectual abilities. Accumulation of amyloid-β (Aβ) peptide, the 
major contributor to the senile plaques central to AD, is thought to mediate neurotoxicity by inducing 
oxidative stress and calcium dysregulation. Transient Receptor Potential Melastatin type 2 (TRPM2) 
is a calcium permeable, non-selective cation channel activated under oxidative stress and ultimately 
induces cell death. The APPSWE/PSEN1∆E9 double transgenic mouse model carries the human 
APPswe (Swedish mutations K594N/M595L) and PS1 mutations with a deletion in exon 9 (PS1-
dE9), and is one of the most commonly used AD model. Both mutations have been shown to be 
linked to Familial (early onset) AD as well as an increased production in Aβ peptides. We propose 
that TRPM2 contributes to pathological deficits in AD. To test this, we crossed TRPM2 knock-out 
with APPSWE/PSEN1∆E9 mice to generate four mouse genotypes (WT, TRPM2 knock-out, 
Alzheimer’s and Alzheimer’s TRPM2 knock-out). We hypothesize that Alzheimer’s TRPM2 knock-
out mice will have improved memory performance when compared to Alzheimer’s mice. To test this 
hypothesis, anxiety, motor activity, recognition memory, as well as spatial learning and memory were 
tested in these mutant mice at 3, 6, 9, 12, and 15 months of age. For these assessments we use open 
field locomotor activity (OFT), elevated plus maze (Elev+), object recognition (OR), Barnes (BM) 
and Morris water maze (MWM) respectively. Our data showed that no genotype difference was 
observed in OFT, Elev+ and OR in terms of hyperactivity, anxiety, and recognition memory. On the 
other hand, our data indicate that Alzheimer’s mice show cognitive impairment (spatial memory 
deficit) compared to WT controls while Alzheimer’s mice without TRPM2 do not, suggesting that 
elimination of TRPM2 activity prevents the spatial learning and memory deficits observed in 
APPSWE/PSEN1∆E9 double transgenic mice.  
 
Key words: Alzheimer’s disease, TRPM2, memory, cognitive impairment, elevated plus maze, open 
field, object recognition, Barnes maze, Morris water maze 
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1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive, degenerative and fatal disease 
characterized by deterioration of cognitive functions such as memory and the ability to 
use judgment and reasoning (Coyle, Price, & Delong, 1983; Cummings, 2004). AD is the 
most common neurodegenerative disease worldwide and is the leading cause of dementia 
(Billings, Oddo, Green, McGaugh, & LaFeria, 2005; Cvetkovic-dozic, Skender-gazibara, 
& Dozic, 2001; Goedert & Spillantini, 2006). At present, AD is prevalent in 
approximately 500,000 Canadians over the age of 65, representing 1.5% of the total 
population in Canada (Alzheimer Society of Canada, 2010). A deterioration of the 
hippocampus and prefrontal cortex, entorhinal cortex, and the basal forebrain cholinergic 
neurons are found to be present in individuals affected by AD (Coyle et al., 1983; 
Gomez-Isla et al., 1996) and the degree of deterioration and the loss of synaptic function 
is shown to be strongly correlated  with the severity of dementia (Scheff & Price, 2003). 
There is currently no cure for AD; however medications such as memantine, donepezil, 
galantamine, and rivastigmine can be used to temporarily alleviate the symptoms of 
dementia (Cummings, 2004).  
The main pathological hallmark of AD is amyloid-beta (Aβ) plaques (Cvetkovic-
dozic et al., 2001; Yankner, Lu, & Loerch, 2008). Aβ plaques are extracellular and are 
composed of Aβ peptides that are 39 to 42 amino acids in length, with Aβ40 and Aβ42 
being the two most common lengths of Aβ found in the brain of AD patients (Oddo et al., 
2003; Selkoe, 2008). These filaments are created by the proteolytic cleavage of the 
transmembrane glycoprotein, amyloid precursor protein (APP). There are two proteolytic 
pathways under which APP is processed: the amyloidogenic pathway which leads to 
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amyloid plaque production and the non-amyloidogenic pathway which does not. In the 
non-amyloidogenic pathway, APP is cleaved by α-secretase and γ-secretase within the 
Aβ domain yielding a soluble N-terminal fragment (sAPPα) and a C-terminal fragment 
(CTFα). These fragments do not accumulate in plaques. However, in the amyloidogenic 
pathway, the cleavage of APP by β-secretase and γ-secretase results in the generation of 
aggregation-prone Aβ peptides, eventually leading to amyloid plaque buildup (Figure 
1.1) (Selcoe, 2001; Selkoe & Schenk, 2003; Xiong, 2011). Mutations in the APP gene 
were found to influence Aβ peptide levels by altering the normal processing of the 
protein, resulting in an elevation in both Aβ40 and 42 peptides (Citron et al., 1992; 
Haass, Hung, Selkoe, & Teplow, 1994; Suzuki et al., 1994) with the latter more likely to 
accumulate in the brain increasing the ratio of Aβ42/Aβ40 (Burdick et al., 1992; Haass & 
Selkoe, 2007; Jarrett & Lansbury, 1993). Presenilin 1 (PS1) and 2 (PS2) were also found 
to play a role in Aβ peptide production. Mutations in these genes were believed to further 
increase Aβ42/ Aβ40 ratio as a result from a reduced γ-secretase activity, which in turn is 
a critical protein involved in the within domain cleavage of the APP gene (Goedert & 
Spillantini, 2006; Hardy & Higgins, 1992; Jankowsky et al., 2004; Xiong et al., 2011). 
Brains affected by AD contain both insoluble and soluble oligomeric assemblies 
(Hardy & Selkoe, 2002; Yu et al., 2009). Aβ peptides have the ability to self-aggregate 
from smaller monomers into readily diffusible oligomers including, dimers, trimers, 
higher order oligomers, as well as fibrils that ultimately accumulate into Aβ plaques. This 
ability to self-aggregate was demonstrated by Pike, Walencewicz, Glabe, & Cotman 
(1991) who identified aggregation in cultured cells that were pre-incubated by the Aβ 
peptide solution for 2-4 days. In addition, Aβ peptides of different lengths were noted to 
 4 
 
have different physical and biological properties (Haass & Selkoe, 2007; Selkoe, 2008; 
Shankar et al., 2008; Townsend et al., 2006). Various studies have examined the 
relationship between Aβ peptide length and its toxicity to cells, with the common 
consensus that soluble forms of oligomers; including dimers and trimers, can cause long-
term potentiation (LTP) deficit and memory impairments in rodents while soluble 
monomers and fibrils cannot (Cleary et al., 2005; Demuro et al., 2005; Shankar et al., 
2008). Dimers however, were found to be more damaging to the cells than trimers 
(Selkoe, 2008; Townsend, Shankar, Mehta, Walsh, & Selkoe, 2006). In keeping with this, 
it is the soluble form of Aβ present in the individual with AD that is most toxic and 
correlate strongly with the disease (Hardy & Selkoe, 2002; Yu et al., 2009). Numerous 
studies have examined the relationship between insoluble Aβ, memory impairment and 
dementia associated with AD. These studies suggest that insoluble Aβ deposition results 
in only minimal neuronal loss (Irizarry, McNamara, Fedorchak, Hsiao, & Hyman, 1997a; 
Irizarry et al., 1997b) and has a weak correlation with memory impairment (Dickson et 
al., 1995; Terry et al., 1991). The latter observation was further confirmed by the 
existence of non-cognitively impaired individuals with high amounts of insoluble Aβ 
deposits in the brain (Delaere et al., 1990; Dickson et al., 1995; Katzman et al., 1988). In 
contrast, soluble Aβ oligomers induce a number of AD-related phenotypes including a 
decrease in dendritic spine density and the disruption of LTP in the hippocampus of 
rodents. These phenomenon correlates to learning and memory as well as impairing 
memory in rats as measured by behavioural tests (Shankar et al., 2008; Townsend et al, 
2006).  
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Figure 1.1. APP processing under amyloidogenic and non-amyloidogenic pathways. 
α-secretase and γ-secretase goes under the non-amyloidogenic pathway to produce 
non-plaque forming Aβ, while β-secretase and γ-secretase goes under the 
amyloidogenic pathway to produce amyloid plaque forming Aβ [Image source: 
http://www.ebi.ac.uk/interpro/potm/2006_7/Page2.htm]. 
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The accumulation of Aβ peptides has been found by numerous studies to mediate 
neurotoxicity by inducing oxidative stress in the brain (Mattson, 1998; Takahashi, Kozai, 
Kobayashi, Ebert, & Mori, 2011). This oxidative stress is formed when an imbalance is 
present between reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), 
reactive nitrogen species (RNS), and antioxidants (Butterfield, 2003; Mattson, 1998; 
Takahashi et al., 2011). This relationship between Aβ peptide accumulation and oxidative 
stress was demonstrated by Misonou, Morishima-Kawashima, & Ihara (2000) using 
human neuroblastoma SH-SY5Y cells. These scientists used H2O2 to induce oxidative 
stress into neuroblastoma cells and observed an increased level of intracellular Aβ 
peptide. In addition, Aβ deposition was also found to take place in the striatum (Klunk et 
al., 2004; Wolfer, Mohajeri, Lipp, & Thal et al., 1998) where oxidative stress may act as 
the key factor of cell death (Lipton, 1999) under states of ischaemia and reperfusion 
(Hawker & Lang, 1990). However, the relationship between Aβ, oxidative stress, and the 
striatum is not well understood.  
In recent studies, there has been evidence supporting that TRPM2 channels are 
important in the pathogenesis of AD. TRPM2 is a ROS/RNS gated channel that has been 
implicated in cell death. ROS/RNS is found to promote TRPM2 activation, leading to a 
disruption in Ca2+ homeostasis and a toxic influx of Ca2+, ultimately inducing cell death 
(Goedert & Spillantini, 2006; Mattson, 2007; Takahashi et al., 2011). Activation by 
ROS/RNS has been attributed to the generation of ADP-ribose (ADPR) which plays a 
key role in the gating of TRPM2 (Perraud et al., 2001). 
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1.2 TRP channels and TRPM2 
Transient receptor potential (TRP) channels are a superfamily of ion channels that are 
non-selective cation channels, most of which have substantial permeability to Ca2+ 
(Nilius & Owsianik, 2011). The first TRP gene described was from the fruit fly 
Drosophila melanogaster where TRP is used for phototransduction purposes (Montell & 
Rubin, 1989). To present day, 28 mammalian TRP channels have been discovered and 
can be subdivided into six main subfamilies including TRPC (canonical), TRPV 
(vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), and TRPA 
(ankyrin).  TRP channels are expressed in almost all cell types in most tissues of the 
human body. These channels are usually localized in the plasma membrane where they 
aid in the transport of Ca2+, Mg2+ and other ions. TRP channels play a critical role in 
regulating various cell functions including immune response and vasomotor functions, 
cold and thermal pain sensing, organ development, and oxidative stress sensing in various 
cells of the body (Nilius, Owsianik, Voets, & Peters, 2007; Nilius & Owsianik, 2011).  
TRPM1 (melastatin) was the first member of the TRPM subfamily and was first 
discovered from melanomas where it served as a tumor suppressor (Duncan et al., 1998). 
There are currently eight family members (TRPM1-TRPM8) present in the TRPM 
subfamily (Jiang, Yang, Zou, & Beech, 2010; Kraft & Harteneck, 2005; Nilius & 
Owsianik, 2011). TRPM may induce cell death under certain conditions given that they 
mediate cellular responses to a range of physiological stimuli and within this family, two 
members (TRPM2 and TRPM7) have been identified to play key roles in cell death 
pathways (McNulty & Fonfria, 2005).   
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Transient Receptor Potential Melastatin type 2 (TRPM2) is a member of the TRPM 
subfamily and is a calcium permeable, non-selective cation channel. It is highly 
expressed in the CNS including the hippocampus, cerebral cortex, thalamus and the 
midbrain (Fonfria et al., 2005; Fonfria et al., 2006; Hara et al., 2002; Kraft et al., 2004; 
Nagamine et al., 1998; Olah et al., 2009; Perraud et al., 2001) and in many tissues outside 
of the CNS including pancreatic β-cells (Qian et al., 2002), bone marrow, spleen, heart, 
as well as in immune cells of the monocytic lineage including monocytes and neutrophils 
(Hara et al., 2002; Perraud et al., 2001; Sano et al., 2001).  
 
1.3 Mouse models of Alzheimer’s disease 
In order to investigate neurodegenerative diseases such as AD, animal models 
have become a common tool used for the better understanding of the pathology, 
underlying mechanisms, and investigation into potential treatments of the disease. While 
invertebrate and primate models are used in some research, rodents are the most common 
and widely used animal models. Due to the fact that the mouse genome can be easily 
manipulated at relatively lower costs, the use of genetically modified mice strains to 
model neurodegenerative diseases such as AD has become extensive (Ghorayeb, Page, 
Gaillard, & Jaber, 2011).  
Pharmacological models and transgenic mouse models have been used for AD. 
Pharmacological models are generated by the direct injection of Aβ peptide into the brain 
of the rodent and can be particularly useful for the understanding of amyloid toxicity. 
However, not all neuropathology are observed in these mouse models of AD, including 
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the loss of neurons and synapses in the cortex and hippocampus, which leads to cognitive 
impairments (Ghorayeb et al., 2011). Unlike pharmacological models, transgenic mouse 
models of AD do not involve injections of Aβ peptides. Instead, they are made from the 
expression of different variants of the APP gene (located on human chromosome 21 
(Xiong et al., 2011)), PS1 or PS2, tau or apolipoprotein E (Ashe, 2001). One of the 
mouse models most commonly used to identify potential therapeutic interventions for AD 
is the APPSWE/PSEN1∆E9 double transgenic mouse line. These mice show both Aβ 
deposition and memory loss (Ashe, 2001; Esh et al., 2005).  
A number of other mouse transgenic lines have been generated using variants of 
the APP and PS1 genes including, the NSE: β-APP751, homozygous for the transgene 
array expressing wild-type human APP751 (Moran, Higgins, Cordell, & Moser, 1995); 
PDAPP, carrying the transgene APP717 expressing the Indiana mutation V717F with a 
portion of APP introns 6-8 (Chen et al., 2000; Duyckaerts, Potier, & Delatour, 2008; Esh 
et al., 2005); TgCRND8, carrying the transgene APP695 expressing both Swedish double 
mutation and the Indiana mutation K670N/M671L and V717F (Duyckaerts et al., 2008; 
Janus et al., 2000); Tg2576, carries the transgene APP695 that expresses the Swedish 
mutation K670N/M671L (Chapman et al., 1999; Duyckaerts et al., 2008; Hsiao et al., 
1996; Kawarabayashi et al., 2001) and APPSWE/PSEN1∆E9, expressing the Swedish 
mutation of K594N/M595L and presenilin-1 mutations with an exon-9 deletion (Bonardi, 
Pulford, Jennings, & Pardon, 2011; Duyckaerts et al., 2008; Malm, Koistinaho, & 
Kanninen, 2011). All of which produce many biochemical, physiological, pathological 
and behavioural characteristics that simulate AD (Ashe, 2001).  
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1.4 APPSWE/PSEN1∆E9 double transgenic mouse model 
The APPSWE/PSEN1∆E9 double transgenic mouse model carries the human 
APPswe (Swedish mutations K594N/M595L) and PS1 mutations with a deletion in exon 
9 (PS1-dE9) (Bonardi et al., 2011; Duyckaerts et al., 2008; Jackson Laboratory, 2013; 
Malm et al., 2011). It was created by coinjection, where each vector containing the 
specific transgene has its own promoter component. In this case, the two specific 
transgenes were Mo/HuAPP695swe and PS1-dE9. Each of these transgenes was then 
inserted into a plasmid at a single locus and each of these plasmids was designed to be 
controlled by an independent mouse prion protein (PrP) promoter. The 
Mo/HuAPP695swe transgene expresses a “humanized” mouse amyloid beta (A4) 
precursor protein gene modified to contain the K595N/M596L mutations that are linked 
to familial Alzheimer’s disease (FAD). The PS1-dE9 transgene expresses the human 
presenilin 1 mutant with the exon-9-deleted also associated with FAD. These two 
plasmids were then coinjected into the B6C3HF2 pronuclei and have co-integrated in the 
genome. Founder line 85 was obtained and by crossing transgenic mice to B6C3F1/J, the 
resulting colony maintained as hemizygotes. Transgenic mice were then backcrossed to 
the background strain C57BL/6J for at least 8 generations (Garcia-Alloza et al., 2006; 
Jackson Laboratory, 2013; Jankowsky et al., 2001).  
APPSWE/PSEN1∆E9 double transgenic mice have been noted to be the best 
characterized AD model to date (Bonardi et al., 2011); both mutations have been shown 
to be linked to FAD, as well as increased production of Aβ40 and Aβ42 peptides (Garcia-
Alloza et al., 2006; Malm et al., 2011; O’Leary and Brown, 2009; Reiserer, Harrison, 
Syverud, & McDonald, 2007; Savonenko et al., 2005; Zhang et al., 2011); Increased 
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production of Aβ42 is one of the triggers of FAD (Savonenko et al., 2005). This increase 
in Aβ42 subsequently results in large senile plaque buildup in the hippocampus, cortex 
and subcortical nuclei (Duyckaerts et al., 2008). Moreover, various transgenic studies 
have shown a direct correlation between the level of Aβ42 and the age at which amyloid 
plaques appear (Jankowsky et al., 2002), with some studies presenting early development 
of amyloid plaques in the hippocampus and cortex observed as early as 4-6 months of age 
(Garcia-Alloza et al., 2006; Ghorayeb et al., 2011; Jackson Laboratory, 2013; Malm et 
al., 2011; Minkeviciene et al., 2008; O’Leary and Brown, 2009; Savonenko et al., 2005). 
Jankowsky et al. (2004), Jardanhazi-Kurutz et al. (2010) and Lalonde, Kim, & Fukuchi 
(2004) have also observed a rapid accumulation of plaques within the cortex and 
hippocampus of these mice at 6 months of age and even greater amounts at 9 (Lalonde et 
al., 2004) and 12 months (Jardanhazi-Kurutz et al., 2010). Likewise, Reiserer et al. 
(2007) found that Aβ plaques start to develop at 6-7 months of age.  
 APPSWE/PSEN1∆E9 bigenic mice have been used extensively for the study of 
cognitive deficits, such as memory impairment observed in humans with AD. A variety 
of tests including open field test (OFT), Elevated plus maze (Elev+ maze), Object 
Recognition (OR), Barnes maze (BM) and Morris Water Maze (MWM) have been 
conducted in these mice to measure their exploratory tendencies, anxiety and memory 
ability. Park et al. (2010) compared the locomotor activity of aged WT with 
APPSWE/PSEN1∆E9 mice and found no difference between the two genotypes. The 
specific age of the mice were not indicated. Likewise, Bonardi et al. (2011) also did not 
see a difference in locomotor activity in 4 months old WT and APPSWE/PSEN1∆E9 
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mice suggesting that at least at young age these mutants do not show changes in 
locomotion behavior.  
Elev+ maze is used to examine greater or lesser anxiety experienced by mice 
through assessing an individual’s exploratory tendencies in walled vs. open arms (Cryan 
& Holmes, 2005; File, 2001). Studies with 7-month-old APPSWE/PSEN1∆E9 mice 
showed that these mutants spend less time in the closed arms than WT mice, suggesting 
that the bigenic mice might be less anxious than WT controls (Lalonde et al., 2004; 
Reiserer et al., 2007).  
To test recognition memory, Bonardi et al. (2011) conducted an object 
recognition test on 4-month-old mice and found no difference between WT and 
APPSWE/PSEN1∆E9 mice. Similar results were observed in a study by Jardanhazi-
Kurutz et al. (2010) using mice at 4 and 6 months of age. Interestingly, 
APPSWE/PSEN1∆E9 mice were found to show severe object recognition memory 
impairment at the age of 9-13 months (Donkin et al., 2010; Yoshiike et al., 2008).  
Spatial learning and memory in rodents were examined in the BM (Sunyer, Patil, 
Hoger, & Lubec, 2007). Studies using 6-7 month old APPSWE/PSEN1∆E9 mice showed 
cognitive impairment in the BM (Reiserer et al., 2007). O’Leary and Brown (2009) also 
observed spatial learning and memory deficits in 16-month-old APPSWE/PSEN1∆E9 
mice. MWM is another test that measures spatial learning and memory. BM and MWM 
are similar because both tests measures spatial learning and memory, however BM is 
conducted on land and MWM in water. Some studies have observed no cognitive deficit 
in APPSWE/PSEN1∆E9 mice at 6 months of age as measured by MWM (Minkeviciene 
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et al., 2008; Savonenko et al., 2005). However, cognitive deficit was observed at 8-12 
months of age (Butovsky et al., 2006; Cao, Lu, Lewis, & Li, 2007; Lalonde et al., 2004; 
Minkeviciene et al., 2008; Oksman et al., 2006), 12-13 months of age (Malm et al., 2011; 
Zhang et al., 2011) and 16-18 months of age (Savonenko et al., 2005). Thus, although 
there is still controversy about when spatial deficits are first observed in this mouse line, 
a number of studies seem to indicate that by 12 months of age APPSWE/PSEN1∆E9 
mice show spatial learning and memory deficits. 
 
1.5 Cell death by oxidative stress and TRPM2-KO mice 
 Calcium is an intracellular messenger that mediates many physiological responses 
of neurons. The concentration of intracellular Ca2+ ([Ca2+]i) fluctuates with time under 
normal physiological conditions and do not result in adverse effects for neurons. 
However, in pathological conditions, the concentration of intracellular Ca2+ may rise 
significantly as H2O2 and Cyclic ADP-ribose (ADPR) activates TRPM2, compromising 
calcium homeostasis in neurons (Mattson, 2007). A loss of calcium homeostasis leads to 
sequential alterations in neuronal function, including disrupting the structure and function 
of synapses, impairment of synaptic plasticity and culminating with cell death. TRPM2 
channels have been shown to play a critical role in cell death (Hara et al., 2002). When 
activated by ADPR and oxidative stress such as H2O2, high levels of Ca2+ will move 
through the channel into the cell resulting in a continued increase in [Ca2+]i, ultimately 
inducing cell death (Fonfria et al., 2004; Hara et al., 2002; Wehage et al., 2002). This link 
between H2O2-induced cell death and TRPM2 channels were investigated by Kaneko et 
al. (2006), who demonstrated that a severe deterioration of primary cultured neurons was 
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present after H2O2 exposure. Similarly, Zhang et al. (2006) demonstrated that activation 
of TRPM2 by oxidative stress triggers apoptotic cell death in hematopoietic cells. Recent 
work by Fonfria et al. (2005) has shown that the inhibition of TRPM2 function reduces 
the increase in [Ca2+]i and toxicity induced by Aβ, and therefore provides concrete 
evidence that TRPM2 may contribute to neuronal cell death under circumstances in 
which oxidative stress are generated. 
 Synaptic plasticity is the ability of synapses to either strengthen or weaken with 
time, in response to increases or decreases in their activity and has been established to be 
Ca2+-dependent (Cavazzini, Bliss, & Emptage, 2005). NMDA (N-methyl-D-aspartate) 
and AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate 
receptors are the two main receptors for the excitatory transmitter, glutamate. The 
opening of NMDA receptors leads to an influx of Ca2+ leading to long-term potentiation 
(LTP) while a more modest influx of Ca2+ into the post-synaptic neuron leads to long-
term depression (LTD). LTP and LTD are thought to represent the cellular basis for 
learning and memory (Bear & Malenka, 1994; Cavazzini et al., 2005). Using 
hippocampal cultures and slices from TRPM2 knockout mice, a recent study by Xie et 
al., (2011) demonstrated that the loss of TRPM2 channels impairs LTD while having no 
effect on LTP.  These findings suggest that TRPM2 contributes to synaptic plasticity. 
Moreover, as TRPM2 is oxidative stress responsive, it is anticipated that oxidative stress 
associated with elevated Aβ in Alzheimer’s mouse models will provoke aberrant TRPM2 
channel activation leading to altered synaptic plasticity. Therefore, eliminating TRPM2 
may be beneficial to learning and memory in mice. 
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 Our hypothesis is that when TRPM2 expression is genetically ablated, there will 
be reduced [Ca2+]i elevation in response to Aβ and therefore reduced toxicity. We believe 
that the loss of TRPM2 expression will better preserve neuronal function and cognition in 
mice. To test that, we will investigate whether knocking out the TRPM2 gene influences 
behavioral deficits observed in the APPSWE/PSEN1∆E9 mouse model of AD. We will 
also investigate whether TRPM2 knockout (TRPM2-KO) mice show any behavioral 
changes. This thesis focuses on 4 genotypes of mice: wild-type mice (WT), TRPM2-KO 
(TRPM2-/-), Alzheimer transgenic (APPSWE/PSEN1∆E9+) and APPSWE/PSEN1∆E9  
TRPM2 knock-out (TRPM2-KO-APPSWE/PSEN1∆E9) mice.  
 
1.6 Hypothesis and Objectives 
TRPM2 is a calcium permeable, non-selective cation channel activated by ADPR and 
oxidants such as hydrogen peroxide (H2O2). Activated TRPM2 causes a continued 
increase in the intracellular Ca2+ concentration and ultimately disrupts neuronal function. 
Given the fact that oxidative stress can promote TRPM2 activation and calcium 
dysregulation, we propose that abnormal TRPM2 activation may contribute to the Aβ-
induced neurotoxicity with consequences for cognitive dysfunction. 
Therefore, we propose that TRPM2 contributes to memory deficits in Alzheimer’s 
disease. To test the hypothesis, we crossed the TRPM2-KO mice with 
APPSWE/PSEN1∆E9 mice in order to conduct cognitive behavioral testing. 
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Section 2 
 
 
MATERIALS AND METHODS 
  
 17 
 
2.1 Animals  
All animal experiments were conducted in accordance to the policies indicated on 
the animal use protocol at Western University. TRPM2 knockout (TRPM2-KO) mice 
were provided by Dr. Yasuo Mori from Kyoto University, Kyoto, Japan. 
APPSWE/PSEN1∆E9 double transgenic mice were provided by Dr. Marco Prado at 
Western University. All mice were housed in the animal facility at Robarts Research 
Institute, Western University. Both mouse strains were on a mixed C57Bl/6J-C3H/HeJ 
background.  
TRPM2 homozygous (TRPM2-/-) mice were crossed with the Alzheimer’s 
transgenic (APPSWE/PSEN1∆E9) bigenic mice to produce TRPM2+/-;APP+ and 
TRPM2+/-;APP-. Heterozygous littermates were then interbred (TRPM2+/-;APP+ x 
TRPM2+/-;APP-) to generate the four genotypes in our study: Wild-type (WT); TRPM2 
knock-out (TRPM2-KO) mice; APPSWE/PSEN1∆E9, and TRPM2 and 
APPSWE/PSEN1∆E9 triple mutants (TRPM2-KO-APPSWE/PSEN1∆E9 ). 
Due to the fact that this is a longitudinal study and that death is common at an 
older age, we added another group of mice to the original cohort at the 6 month time 
point and continued experimentation as to make sure the N value will not be too low. 
 
2.2 General materials and methods 
This study was done longitudinally using the same cohort of mice. Only male 
mice were used. We did not use females since their estrous cycle may interfere with our 
experiments. 
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Anxiety, motor activity, recognition memory, spatial learning and memory were 
tested in mice at 3, 6, 9, 12, and 15 month time points, as measured by the open field 
locomotor activity (OFT), elevated plus (Elev+), object recognition(OR), Barnes (BM) 
and Morris water maze (MWM) respectively. 
For all behaviour tests, 70% ethanol was used prior to each mouse trial to 
obliterate any odour cues left from the previous individual, thus preventing bias in our 
results. In order to reduce the level of stress experienced by these mice so that 
behavioural responses will not be influenced, all individuals were placed in the test room 
before experimentation was to begin and were given a thirty minute habituation session.  
In order to minimize any alteration in these rodents’ behaviour while the observer 
is in the room, all experimental apparatus were placed at the back of the testing room 
with a curtain hanging from the ceiling, separating the area where the maze and observer 
are located (Vorhees & Williams, 2006; Walf & Frye, 2007). All tests were conducted in 
the same animal facility located at Robarts Research Institute between 0900 and 1700 
hours.   
 
2.3 Open field locomotor activity 
Locomotor activity was measured using an automated system (Figure 2.1) 
(Versamax animal activity monitor; Accuscan Instruments, Inc., Columbus, OH, USA). 
Vertical light beam holes are positioned at the base of the monitors to record activities of 
mice. When mice move about the activity chamber, these light beams are interrupted, and 
these light beam breaks are then converted to distance (cm) for simple data analysis of 
activity (Sotnikova et al., 2004; de Castro et al., 2009a; de Castro et al., 2009b). 
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Mice were placed into several 20 cm x 20 cm locomotor activity chambers made 
out of plexiglass with 30.5 cm high walls and left alone for two hours, while the 
automated activity monitor recorded the discrete movements of mice including total 
distance travelled during exploration, total number of rear movements, and the amount of 
time spent in the center which is a measure of anxiety. All activities were measured in 
blocks of five minute intervals. 
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Figure 2.1. Automated Locomotor activity chamber used to measure locomotor 
activity. [Image source: http://phenome.jax.org]. 
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2.4 Elevated plus maze 
A standard elevated plus maze (Med Associates Inc., St. Albans, VT, USA) was 
used in this test, as seen in Figure 2.2. This maze is composed of opaque white acrylic 
material and consists of four arms, each being 38 cm long and 6 cm wide. Two of the 
arms are open without walls and the other two arms were enclosed by black 
polypropylene walls of 20 cm in height. The maze is elevated 75 cm off the floor with 
metal legs supporting each arm. A camera mounted overhead on the ceiling is used to 
record the animals’ movements on the maze, while this behaviour data are automatically 
collected with the ANY-maze video-tracking system (Stoelting Co., Wood Dale, IL, 
USA).  
Each mouse is placed in the center of the maze facing the open arm and is then 
allowed to explore the maze for 5 minutes while the video tracking system automatically 
records the animals’ movements. During this time, different variables were recorded 
including the total distance travelled, latency to enter each arm, the number of entries into 
and the amount of time individual mice spent in each arm. 
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Figure 2.2. A standard elevated plus maze used to measure anxiety responses of 
rodents. [Image source: 
http://iobs.fudan.edu.cn/En/techs_view.asp?id=27&EnBigclassname=Animal%20Model
%20and%20Behavior%20Facility&EnSmallclassname=Equipments]. 
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2.5 Object recognition 
Object recognition test was performed over the course of 2d and consisted of a 1d 
learning trial and a 1d testing trial. Each mouse was placed in a shoebox cage (homecage) 
(Figure 2.3) in the test room and given a 30 minute habituation session before the test 
was to begin. Training was conducted immediately following habituation on day 1, where 
two identical objects were positioned on the opposite ends of the homecage at a fixed 
distance. The mouse was then left to explore its surroundings for 5 minutes. Each mouse 
underwent three trials on training day. After a latency of 24 hours, mice were presented 
with one familiar object and one novel object in the same homecage. Exploration was 
again recorded for 5 minutes. Exploration was defined as either sniffing or touching the 
object with the nose and/or forepaw (de Lima et al. 2005). All objects had similar 
colours, textures, and sizes, but distinctive shapes.  
A counterbalance measure was created prior to experimentation in order to 
randomly assign the mouse with their familiar and novel object. The ANY-maze video 
system (Stoelting Co., Wood Dale, IL, USA) was used to record the animals’ movements.  
While the video records, the observer uses stopwatches to manually record the 
time each mouse spends exploring either the familiar or novel object.  
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Figure 2.3. Homecage used during training and test days for object recognition. Red 
circles represent familiar objects, while purple square represent the novel object. 
[Image adapted from 
http://www.nature.com/ncomms/journal/v1/n6/images_article/ncomms1064-f1.jpg]. 
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2.6 Barnes maze 
Barnes maze is made up of a white opaque circular platform (91.5cm in diameter) 
made of a plastic material, elevated 105cm above the floor, with 20 holes equally spaced 
around the perimeter (5cm in diameter; 7.5cm between holes) (Figure 2.4) (Sandiego 
Instruments, San Diego, CA, USA). An escape box or target hole (5cm x 11cm x 5cm) 
acts as positive reinforcement since they provide the mice with an escape from the 
brightly lit and exposed platform. The location of the escape box depends on the 
counterbalance made prior to experimentation. All holes need to look identical to avoid 
any potential behavioural bias that could arise.  
In order to motivate mice so they will escape from the platform and into the 
escape box, a weak aversive stimulus (sound of a buzzer) is applied; the same parameters 
of the sound were used throughout the experiment. Visual cues of different shapes and 
colors were placed on the walls surrounding the maze. These cues act as the animal’s 
reference points for locating the target hole (Sunyer et al., 2007).  
The Barnes maze test was performed over the course of 6d and consisted of a 4d 
acquisition trial (4 trials per day) and a 2d (1 trial per day) testing trial. For the adaptation 
period on the first trial of the first day of training, the mouse was placed in a cylindrical 
white start chamber at the center of the maze. After 10 seconds, the chamber was lifted 
and the mouse guided to the escape box, again with the sound of a buzzer acting as a 
weak aversive stimulus to provide increased motivation for the mouse to escape from the 
platform and into the escape box.  
Spatial acquisition follows the adaptation period, where each mouse was given 3 
minutes on the maze to locate the escape box. A camera mounted overhead on the ceiling 
is used to record the animals’ movements on the maze, while this behaviour data are 
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automatically collected with the ANY-maze video-tracking system (Stoelting Co., Wood 
Dale, IL, USA). The variables collected include the primary and total latency to get to 
target, primary and total number of errors, as well as total distance travelled. 
To test reference memory, either short or long-term retention in these mice, two 
probe trials are conducted after training, with the first trial performed on day 5 and the 
second trial on day 12. In these trials, the number of times a mouse pokes its nose into or 
hovers its head above the escape box are recorded, also with the automated video-
tracking system.  
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Figure 2.4. Barnes maze used to measure spatial learning and memory, including 
distal visual cues used during experimentation. 
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2.7 Morris Water maze and reversal 
The Morris water maze (MWM) (Med Associates Inc., St. Albans, VT, USA) is 
made up of a smooth white opaque plastic pool 120cm in diameter and 40cm in height for 
the walls. The pool was filled approximately half way with clear water kept at 
temperatures ranging from 24-26°C with a circular escape platform 10cm in diameter 
submerged 1cm below the surface of the water. Two axes were designated for the maze, 
creating an imaginary “+” in the pool leading to the formation of four equal quadrants 
numbered 1-4 with the platform positioned in the middle of one quadrant. The location of 
the quadrant depends on the counterbalance made prior to experimentation where at least 
one-quarter of the animals are tested with the platform in each individual quadrants.  
This behaviour data were automatically collected with the ANY-maze video-
tracking system (Stoelting Co., Wood Dale, IL, USA) (Figure 2.5).  
Visual cues of different colours and shapes (gift wrap bows, large decorative 
flower, and plastic Hawaiian leis) were used as a guide to the escape box and were placed 
on the walls surrounding the maze. These cues act as the animal’s reference points for 
locating the target quadrant (Vorhees & Williams, 2006).  
The MWM requires 4d of acquisition (4 trials per day) and 1d of testing (1 trial 
per day). In the acquisition phase (days 1-4), the mouse was released into the water at the 
desired start position of the maze, facing the pool wall. The mouse was then required to 
locate the hidden platform with the guidance of visual cues on the walls surrounding the 
maze. Once the mouse reaches the platform, the video-tracking system is stopped by the 
experimenter and variables such as the total distance travelled, the escape latency, and 
speed are recorded. In order to assess the retention of spatial memory, specifically short- 
term memory, a probe trial was performed 24 hours after the last training trial. The 
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platform was removed in the test trial and mice were allowed to swim freely for 60 
seconds. During this session, the amount of time spent in each of the quadrants was 
measured (Faivre, Hamilton, & Holscher, 2012; Vorhees & Williams, 2006).  
MWM reversal was conducted the week after MWM, under identical conditions 
and methodology with the only difference being the location of the platform. In this 
reversal learning period, the platform was relocated to the quadrant opposite of its 
previous location.  
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Figure 2.5. Morris water maze used to measure spatial learning and memory, 
including distal visual cues used during experimentation. 
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2.8 Statistical Analysis 
 All data are expressed as mean ± SEM. Statistical analyses were carried out using 
SigmaStat® (Aspire Software International, Ashburn, VA). Graphs were constructed 
using GraphPad Prism® (GraphPad Software, San Diego, CA). Repeated measures one-
way and two-way ANOVA followed by the Holm-Sidak post hoc comparison test were 
used (where appropriate) to compare multiple groups. Results were considered significant 
when p < 0.05. 
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3.1 Open field locomotor activity 
 
An open field activity test was conducted to measure locomotor activity in mice 
of all genotypes. In addition to measuring locomotion, the open field test can also 
measure anxiety levels in rodents. Mice have a natural tendency to avoid open spaces by 
travelling along the walls of enclosures as a means of protection and easy escape 
(Lalonde et al., 2004). Therefore, the amount of time individuals spent in the center area 
of the open field test provides a measure of anxiety. 
 No statistical differences in locomotor activity were observed between genotypes 
at three months (Fig.3.1A,B; F(3,920) = 1.105, p = 0.358; there was no interaction 
between genotype x time - Fig.3.1 A,B; F(69,920) = 0.669, p = 0.982; and habituation to the 
novel environment was found to occur for mice from all four genotypes, indicated by a 
continued decrease in distance with time - Fig.3.1A; F(69,920) = 0.669, p = 0.982); six 
months (Fig.3.2A,B; F(3,1081) = 0.369, p = 0.775;  there was no interaction between 
genotype x time - Fig.3.2A,B; F(69,1081) = 0.850, p = 0.803; and habituation to the novel 
environment was found to occur for mice from all four genotypes - Fig. 3.2A; F(23,1081) = 
51.910, p < 0.001); or nine months (Fig.3.3A,B; F(3,897) = 0.701, p = 0.557; there was no 
interaction between genotype x time - Fig.3.3A,B; F(69,897) = 1.031, p = 0.412; and 
habituation to the novel environment was found to occur for mice from all four genotypes 
- Fig.3.3A; F(23,897) = 44.401, p < 0.001). Furthermore, no change was observed in terms 
of the amount of time spent in the center of the chamber at these different time points 
(three months: Fig.3.1C; F(3,920) = 2.016, p = 0.127; six months: Fig.3.2C; F(3,1081) = 
0.755, p = 0.525; and nine months: Fig.3.3C; F(3,897) = 0.370, p = 0.775).  
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At twelve months, no difference in locomotor activity was observed between 
TRPM-KO and WT mice. However, APPSWE/PSEN1∆E9  and TRPM2-KO-
APPSWE/PSEN1∆E9 mice showed significantly decreased horizontal activity 
(Fig.3.4A,B; F(3,1035) = 3.745, p = 0.017; post hoc analysis show p<0.05). In addition, 
APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice spent less time in 
the center than the control mice (Fig.3.4C; p < 0.01 and p < 0.01 respectively, in the 
Holm-Sidak post-hoc test). However, this difference in center time might reflect the fact 
that these mutant mice are hypoactive rather than any difference in anxiety.   
Unfortunately, for the fifteen months analysis we had a smaller number of mice 
due to death or fight injury. Our analysis did not show any significant difference in 
locomotor activity between genotypes (Fig.3.5A,B; F(3,374) = 1.622, p = 0.202). A 
statistical significance in center time was observed between genotypes as measured by 
two-way repeated measures ANOVA. Post hoc analysis indicates that 
APPSWE/PSEN1∆E9 mice spent significantly less time in the center than WT, TRPM2-
KO and TRPM2-KO-APPSWE/PSEN1∆E9 mice (Fig.3.5C). 
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Figure 3.1. Locomotor activity at 3 months of age 
(A) Horizontal activity in an open field for WT, TRPM2-KO, APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice was measured over time (F(23,920) = 61.052, 
p < 0.001 in a two-way repeated measures ANOVA) and (B) cumulatively over 2 h and 
(C) amount of time spent in the center. All data were plotted as Mean ± SEM. 
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Figure 3.2. Locomotor activity at 6 months of age 
 (A) Horizontal activity in an open field for WT, TRPM2-KO, APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice was measured over time (F(23,1081) = 51.910, 
p < 0.001 in a two-way repeated measures ANOVA) and (B) cumulatively over 2 h and 
(C) amount of time spent in the center. All data were plotted as Mean ± SEM. 
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Figure 3.3. Locomotor activity at 9 months of age 
 (A) Horizontal activity in an open field for WT, TRPM2-KO, APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice was measured over time (F(23,897) = 44.401, 
p < 0.001 in a two-way repeated measures ANOVA) and (B) cumulatively over 2 h and 
(C) amount of time spent in the center. All data were plotted as Mean ± SEM. 
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Figure 3.4. Locomotor activity at 12 months of age 
(A) Horizontal activity in an open field for WT, TRPM2-KO, APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice was measured over time (F(23,1035) = 50.049, 
p < 0.001 in a two-way repeated measures ANOVA) and (B) cumulatively over 2 h and 
(C) amount of time spent in the center. All data were plotted as Mean ± SEM. *p = 0.05 
in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-Sidak post hoc test. 
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Figure 3.5. Locomotor activity at 15 months of age  
(A) Horizontal activity in an open field for WT, TRPM2-KO, APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice was measured over time (F(11,374) = 26.461, 
p < 0.001 in a two-way repeated measures ANOVA) and (B) cumulatively over 2 h and 
(C) amount of time spent in the center. All data were plotted as Mean ± SEM. **p < 0.01 
in a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc test. 
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3.2 Elevated Plus maze 
The elevated plus maze task was used to examine whether anxiety levels differed 
between the four genotypes of mice (WT, TRPM2-KO, APPSWE/PSEN1∆E9, and 
TRPM2-KO-APPSWE/PSEN1∆E9) at five age points (3, 6, 9, 12, and 15 months).  
No statistical differences in anxiety were observed between genotypes at three 
months (Fig.3.6A; F(3,28) = 0.152, p = 0.928 in terms of the percentage of time spent in 
open arms; there was no statistical difference in terms of the number of arm entries to the 
open arms – Fig.3.6B; F(3,28) = 0.121, p = 0.947); nine months (Fig.3.6E; F(3,32) = 0.551, 
p = 0.651 in terms of the percentage of time spent in open arms; there was no statistical 
difference in terms of the number of arm entries to the open arms – Fig.3.6F; F(3,32) = 
1.248, p = 0.309); or fifteen months (Fig.3.6I; F(3,30) = 1.241, p = 0.312 in terms of the 
percentage of time spent in open arms; there was no statistical difference in terms of the 
number of arm entries to the open arms – Fig.3.6J; F(3,30) = 1.296, p = 0.294).  
At six months, while TRPM2-KO and APPSWE/PSEN1∆E9 mice did not differ 
significantly from WT in the time spent in the open arms; TRPM2-KO-
APPSWE/PSEN1∆E9 mice spent significantly longer time in the open arms than the 
control mice (Fig.3.6C; F(3,33) = 3.756, p = 0.020; post hoc analysis show p<0.05 and 
p<0.01). However, no statistical difference was observed between genotypes in terms of 
the number of arm entries into the open arms (Fig.3.6D; F(3,33) = 2.023, p = 0.130). These 
results might suggest that TRPM2-KO-APPSWE/PSEN1∆E9 mice were less anxious 
than WT, TRPM2-KO and APPSWE/PSEN1∆E9 at this age.  
No statistical difference was observed in the percentage of time spent in the open 
arms at twelve months of age (Fig.3.6G; F(3,31) = 0.417, p = 0.742). On the other hand, 
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APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice visited the open 
arms significantly fewer times than the control mice (Fig.3.6H; F(3,31) = 5.799, p = 0.003; 
post hoc analysis show p<0.05 and p<0.01), suggesting that at this age these mutant mice 
might be more anxious than WT and TRPM2-KO. However, this may also be a 
consequence of their reduced activity when aged. 
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Figure 3.6. Assessment of anxiety at 3, 6, 9, 12, and 15 months of age 
 
(A) Percentage of time WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-
APPSWE/PSEN1∆E9 mice spent in the open arms measured at 3 months (B) Number of 
arm entries measured at 3 months and (C) Percentage of time spent in open arms 
measured at 6 months (F(3,33) = 3.756, p < 0.05 in a one-way repeated measures ANOVA) 
(D) Number of arm entries measured at 6 months and (E) Percentage of time spent in 
open arms measured at 9 months and (F) Number of arm entries measured at 9 months 
(G) Percentage of time spent in open arms measured at 12 months and  (H) Number of 
arm entries measured at 12 months (F(3,31) = 5.799, p < 0.01 in a one-way repeated 
measures ANOVA) (I) Percentage of time spent in open arms measured at 15 months of 
age and (J) Number of arm entries measured at 15 months of age. All data were plotted as 
Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-Sidak post 
hoc test. 
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3.3 Object recognition 
 
To test for recognition memory, which is the ability of mice to discriminate 
between familiar and novel objects, we conducted an object recognition test at 9 and 12 
months. Mice have a spontaneous tendency to spend more time exploring a novel object 
than a familiar one. Therefore, the choice to explore the novel object will reflect the use 
of learning and recognition memory (Otalora et al., 2012; Prado et al., 2006). This task 
requires that the individuals be able to distinguish between the two familiar objects on 
training day and recognize the novel object on test day where both familiar and novel 
objects are present. Although we are showing only the 9 and 12 months data here, we did 
conduct this test at 3 and 6 months of age. However, our protocol was flawed and 
therefore we could not use those results. The protocol was modified in order to conduct 
the test at 9 and 12 months of age. We decided not to conduct object recognition test at 
15 months of age because we assumed no deficit will be seen; that mice of all genotypes 
will be able to discriminate between the familiar and novel objects, just like the data 
shown at 9 and 12 months. 
No significant difference was observed in terms of the percentage of time spent 
exploring the familiar (F) and novel (N) objects. Mice from all genotypes preferred the 
novel object on testing day, as shown by an increased exploration of N at nine months 
(Fig.3.7B; WT - F(1,5) = 33.235, p = 0.002; post hoc analysis show p<0.01; TRPM2-KO - 
F(1,5) = 17.506, p = 0.009; post hoc analysis show p<0.01; APPSWE/PSEN1∆E9 - F(1,9) = 
7.625, p = 0.022; post hoc analysis show p<0.01; TRPM2-KO-APPSWE/PSEN1∆E9  
- F(1,11) = 12.696, p = 0.004; post hoc analysis show p<0.01) and twelve months 
(Fig.3.7D; WT - F(1,7) = 10.469, p = 0.014; post hoc analysis show p<0.01; TRPM2-KO - 
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F(1,7) = 27.963, p = 0.001; post hoc analysis show p<0.01; APPSWE/PSEN1∆E9- F(1,11) = 
6.621, p = 0.026; post hoc analysis show p<0.05; TRPM2-KO-APPSWE/PSEN1∆E9  
- F(1,13) = 20.757, p < 0.001; post hoc analysis show p<0.01). 
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Figure 3.7. Assessment of recognition memory at 9 and 12 months of age 
 (A) The time that WT, TRPM2-KO, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice spent exploring the homecage on training trials 1-3 and test 
trial 4 was measured at 9 months and (C) 12 months. (B) Percentage of time mice spent 
exploring the familiar (F) and novel (N) objects on both training and test days were 
measured at 9 months and (D) 12 months. All data were plotted as Mean ± SEM. *p < 
0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-Sidak post hoc test. 
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3.4 Barnes maze 
Spatial learning and memory were examined in the Barnes maze (Sunyer et al., 
2007) for all four groups of mice at 3, 6, 9, 12, and 15 months of age. Learning was 
observed for all ages as measured by the primary latency to find the escape box, indicated 
by the reduced time needed for the mice to find the escape box. Primary number of 
errors, the number of errors made by the mice in order to reach the target hole was also 
measured. Memory, or the ability to remember the location of the target hole with the 
guidance of visual cues, was assessed on test/probe days 5 and 12. Here, the number of 
times the mouse pokes its nose into, or hover its head above the escape box was 
measured. 
No statistical differences in spatial memory was observed between genotypes at 
three months (there was no statistical difference between genotypes in terms of primary 
latency to target hole for training days 1 to 4 as well as testing days 5 and 12 - Fig.3.8A 
(left); F(3,195) = 1.128, p = 0.350; there was no statistical difference between genotypes in 
terms of primary latency to target hole when only looking at training days – Fig.3.8A 
(middle); F(3,117) = 0.861, p = 0.469; and there was no statistical difference between 
genotypes in terms of primary number of errors to target hole on training days – Fig.3.8A 
(right); F(3,117) = 1.167, p = 0.335. There was no statistical difference between genotypes 
on test day 5 (Fig.3.8B (left); F(3,117) = 1.213, p = 0.318) or day 12 (Fig.3.8C (left); F(3,117) 
= 2.807, p = 0.052) in terms of number of times the mouse pokes its nose into the escape 
box. 
 At six months, APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9  
mice showed longer primary latency to the target hole than control mice - Fig.3.9A (left); 
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F(3,230) = 4.051, p < 0.05; post hoc analysis show p≤0.01 and p<0.05; 
APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice also showed  longer 
primary latency to the target hole than control mice over the 4 days of training - Fig.3.9A 
(middle); F(3,138) = 4.125, p < 0.05; post hoc analysis show p<0.01 and p<0.05; and 
APPSWE/PSEN1∆E9 mice made more errors compared to the others throughout the 4 
training days – Fig.3.9A (right); F(3,138) = 2.970, p <0.05; post hoc analysis show p<0.05. 
On probe trial day 5, latency to find the target hole was no different between genotypes 
(Fig 3.9A (left)) and time spent investigating the target quadrant was significantly longer 
compared with the other quadrants for all genotypes (Fig.3.9B (left); F(3,138) = 3.176, p = 
0.033; post hoc analysis show p<0.05; all mice visited the target hole location more 
regardless of genotypes as indicated by the percentage of time spent in each quadrant - 
Fig.3.9B (right); F(3,138) = 91.008, p < 0.001; post hoc analysis show p<0.001. On probe 
trial day 12, even though APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9  
mice visited the target hole significantly less than controls - Fig.3.9C (left); F(3,138) = 
4.512, p = 0.007; post hoc analysis show p<0.05 and p<0.01, the results indicate that 
these mutants do remember the position of the target hole. 
At nine months, there was no statistical difference between genotypes in terms of 
primary latency to target hole for training days 1 to 4 as well as testing days 5 and 12 - 
Fig.3.10A (left); F(3,230) = 2.269, p = 0.093; there was no statistical difference between 
genotypes in terms of primary latency to target hole when only looking at training days – 
Fig.3.10A (middle); F(3,138) = 1.631, p = 0.195; and there was no statistical difference 
between genotypes in terms of primary number of errors to target hole on training days – 
Fig.3.10A (right); F(3,138) = 0.506, p = 0.680. On probe trial day 5, APPSWE/PSEN1∆E9  
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and TRPM2-KO-APPSWE/PSEN1∆E9 mice visited the target hole location significantly 
less than controls - Fig.3.10B (left); F(9,138) = 3.223, p = 0.001; post hoc analysis show 
p≤0.001 and p<0.05; TRPM2-KO-APPSWE/PSEN1∆E9 mice also visited the left hole 
location significantly less than controls - Fig.3.10B (left); F(9,138) = 3.223, p = 0.001; post 
hoc analysis show p<0.05; all mice visited the target hole location more regardless of 
genotypes on this day as indicated by the percentage of time spent in each quadrant - 
Fig.3.10B (right); F(3,138) = 103.229, p < 0.001; post hoc analysis show p<0.001; and 
there was no statistical difference between genotypes on test day 12 – Fig.3.10C (left); 
F(9,138) = 1.407, p = 0.191); again, all mice visited the target hole location more regardless 
of genotypes as indicated by the percentage of time spent in each quadrant - Fig.3.10C 
(right); F(3,138) = 68.221, p < 0.001; post hoc analysis show p<0.001 and p < 0.01.  
At twelve months, there was no statistical difference between genotypes in terms 
of primary latency to target hole for training days 1 to 4 as well as testing days 5 and 12 
(Fig.3.11A (left); F(3,185) = 0.856, p = 0.472); there was no statistical difference between 
genotypes in terms of primary latency to target hole when only looking at training days – 
Fig.3.11A (middle); F(3,111) = 0.575, p = 0.635; and there was no statistical difference 
between genotypes in terms of primary number of errors to target hole on training days – 
Fig.3.11A (right); F(3,111) = 1.129, p = 0.350. On probe trial days 5 and 12, while target 
hole location visits of TRPM2-KO and TRPM2-KO-APPSWE/PSEN1∆E9 mice did not 
differ from that of WT, APPSWE/PSEN1∆E9 mice visited the target hole location 
significantly less than control and TRPM2-KO-APPSWE/PSEN1∆E9 mice - Fig.3.11B 
(left); F(3,111) = 2.284, p = 0.035; post hoc analysis show p<0.01 and p<0.05; and 
Fig.3.11C (left); F(3,111) = 1.789, p = 0.05; post hoc analysis show p<0.05. All mice 
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visited the target hole location more regardless of genotypes on both day 5 (Fig.3.11B 
(middle); F(3,111) = 59.827, p < 0.001; post hoc analysis show p<0.001 and p<0.01) and 
day 12 (Fig.3.11C (middle); F(3,111) = 54.250, p < 0.001; post hoc analysis show p<0.001 
and p<0.01) as indicated by the percentage of time spent in each quadrant. 
At fifteen months, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice had longer primary latency to target hole than control mice 
(Fig.3.12A (left); F(3,200) = 7.198, p < 0.001; post hoc analysis show p<0.001 and 
p<0.01); APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice also had 
longer primary latency to target hole than control mice when only looking at the first 4 
training days (Fig. 3.12A (middle); F(3,120) = 4.763, p < 0.01; post hoc analysis show 
p<0.01 and p<0.05); and there was no statistical difference between genotypes in terms of 
primary number of errors to target hole on training days (Fig.3.12A (right); F(3,120) = 
0.803, p = 0.499). On probe trial day 5, APPSWE/PSEN1∆E9 mice visited the target hole 
location significantly less than control and TRPM2-KO-APPSWE/PSEN1∆E9 mice 
(Fig.3.12B (left); F(9,120) = 4.344, p < 0.001; post hoc analysis show p<0.001 and p<0.05). 
On probe trial day 12, APPSWE/PSEN1∆E9 mice visited the target hole location 
significantly less than control and TRPM2-KO-APPSWE/PSEN1∆E9 mice (Fig.3.12C 
(left); F(9,120) = 2.006, p = 0.044; post hoc analysis show p<0.01). Thus, 
APPSWE/PSEN1∆E9 mice visited less and spent significantly less time in the target 
quadrant on both probe days compared to TRPM2-KO-APPSWE/PSEN1∆E9 mice. 
These results indicate that TRPM2-KO-APPSWE/PSEN1∆E9 mice perform significantly 
better than APPSWE/PSEN1∆E9 mice.   
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Taking all of the above findings into consideration, results from BM indicate that 
APPSWE/PSEN1∆E9 mice have impaired spatial memory and that AD mouse model 
that lack TRPM2 (TRPM2-KO-APPSWE/PSEN1∆E9) had their performance rescued in 
the Barnes maze. 
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Figure 3.8. Barnes Maze assessment of spatial memory at 3 months of age. 
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(A (left)) Primary latency to target hole on acquisition days 1-4 (the average values of 
four 3min trials per day are plotted) and test days 5 and 12 was measured for WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 3 
months. (A (middle)) Primary latency to target hole on acquisition days 1-4 (the average 
values of four 3min trials per day are plotted) was measured for WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 , and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 3 months. (A 
(right)) Primary number of error to target hole on acquisition days 1-4 was measured for 
all genotypes at 3 months. (B (left)) Number of nose pokes per quadrant measured on test 
day 5 in a 90s probe trial. (B (middle)) Percentage of nose pokes per quadrant separated 
by genotypes on day 5. (B (right)) Representative path traces on day 5 comparing WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice. 
Target hole indicated by black dot. (C (left)) Number of nose pokes per quadrant 
measured on test day 12 in a 90s probe trial. (C (middle)) Percentage of nose pokes per 
quadrant separated by genotypes on day 12. (C (right)) Representative path traces on day 
12 comparing WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-
APPSWE/PSEN1∆E9 mice. All data were plotted as Mean ± SEM.  *p < 0.05 in a Holm-
Sidak post hoc test; **p < 0.01 in a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-
Sidak post hoc test; ***’p = 0.001 in a Holm-Sidak post hoc test. L, left; O, opposite; R, 
right; T, target. 
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Figure 3.9. Barnes Maze assessment of spatial memory at 6 months of age. 
(A (left)) Primary latency to target hole on aquisition days 1-4 (the average values of four 
3min trials per day are plotted) and test days 5 and 12 was measured for WT, TRPM2-
KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 6 months 
(F(3,230) = 4.051, p < 0.05 in a two-way repeated measures ANOVA). (A (middle)) 
1 2 3 4 5 12
0
10
20
30
40
50
60
*,**
*,**'
Day
Pr
im
ar
y 
La
te
n
cy
 
(se
c)
1 2 3 4
0
10
20
30
40
50
60
Day
Pr
im
ar
y 
La
te
n
cy
 
(se
c)
*,**
*,**
1 2 3 4
0
5
10
15
20
Day
Pr
im
ar
y 
# 
o
f E
rr
o
rs
*,**'
Target Opposite Left Right
0
5
10
15
20
25
30
35
*
*
*
Quadrant
# 
o
f P
o
ke
s
T O L R T O L R T O L R T O L R
0
2
4
6
Quadrant
%
 
No
se
 
Po
ke
s
***
*** ***
***
Target Opposite Left Right
0
5
10
15
20
25
30
35
*,** **
*
*,**
*
Quadrant
# 
o
f P
o
ke
s
T O L R T O L R T O L R T O L R
0
1
2
3
4
5
Quadrant
%
 
No
se
 
Po
ke
s
***
*** ***
***
A 
B 
C 
Probe Day 5 
Probe Day 12 
 
B 
C 
 55 
 
Primary latency to target hole on acquisition days 1-4 (the average values of four 3min 
trials per day are plotted) was measured for WT, TRPM2-KO, APPSWE/PSEN1∆E9, 
and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 6 months (F(3,138) = 4.125, p < 0.05 in a 
two-way repeated measures ANOVA). (A (right)) Primary number of error to target hole 
on acquisition days 1-4 was measured for all genotypes at 6 months (F(3,138) = 2.970, p < 
0.05 in a two-way repeated measures ANOVA). (B (left)) Number of nose pokes per 
quadrant measured on test day 5 in a 90s probe trial (F(3,138) = 3.176, p < 0.05 in a two-
way repeated measures ANOVA). (B (right)) Percentage of nose pokes per quadrant 
separated by genotypes on day 5 (F(3,138) = 91.008, p < 0.001 in a two-way repeated 
measures ANOVA). (C (left)) Number of nose pokes per quadrant measured on test day 
12 in a 90s probe trial (F(3,138) = 4.512, p < 0.01 in a two-way repeated measures 
ANOVA). (C (right)) Percentage of nose pokes per quadrant separated by genotypes on 
day 12 (F(3,138) = 80.773, p < 0.001 in a two-way repeated measures ANOVA). All data 
were plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a 
Holm-Sidak post hoc test; **’p = 0.01 in a Holm-Sidak post hoc test; *** p < 0.001 in a 
Holm-Sidak post hoc test. L, left; O, opposite; R, right; T, target. 
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Figure 3.10. Barnes Maze assessment of spatial memory at 9 months of age 
(A (left)) Primary latency to target hole on acquisition days 1-4 (the average values of 
four 3min trials per day are plotted) and test days 5 and 12 was measured for WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 9 
months. (A (middle)) Primary latency to target hole on acquisition days 1-4 (the average 
values of four 3min trials per day are plotted) was measured for WT, TRPM2-KO, 
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APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 9 months. (A 
(right)) Primary number of error to target hole on acquisition days 1-4 was measured for 
all genotypes at 9 months. (B (left)) The number of nose pokes per quadrant were 
measured on test day 5 in a 90s probe trial (F(9,138) = 3.223, p = 0.001 in a two-way 
repeated measures ANOVA). (B (right)) Percentage of nose pokes per quadrant separated 
by genotypes on day 5 (F(9,138) = 103.229, p < 0.001 in a two-way repeated measures 
ANOVA). (C (left)) The number of nose pokes per quadrant were measured on test day 
12 in a 90s probe trial. (C (right)) Percentage of nose pokes per quadrant separated by 
genotypes on day 12 (F(9,138) = 68.221, p < 0.001 in a two-way repeated measures 
ANOVA). All data were plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc 
test; **p < 0.01 in a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc 
test; ***’p = 0.001 in a Holm-Sidak post hoc test. L, left; O, opposite; R, right; T, target. 
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Figure 3.11. Barnes Maze assessment of spatial memory at 12 months of age 
(A (left)) Primary latency to target hole on acquisition days 1-4 (the average values of 
four 3min trials per day are plotted) and test days 5 and 12 was measured for WT, 
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TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 12 
months. (A (middle)) Primary latency to target hole on acquisition days 1-4 (the average 
values of four 3min trials per day are plotted) was measured for WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 , and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 12 months. (A 
(right)) Primary number of error to target hole on acquisition days 1-4 was measured for 
all genotypes at 12 months. (B (left)) The number of nose pokes per quadrant were 
measured on test day 5 in a 90s probe trial (F(3,111) = 2.284, p = 0.035 in a two-way 
repeated measures ANOVA). (B (middle)) Percentage of nose pokes per quadrant 
separated by genotypes on day 5 (F(9,111) = 59.827, p < 0.001 in a two-way repeated 
measures ANOVA). (B (right)) Representative path traces on day 5 comparing WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice. 
Target hole indicated by black dot. (C (left)) The number of nose pokes per quadrant 
were measured on test day 12 in a 90s probe trial (F(3,111) = 1.789, p = 0.05 in a two-way 
repeated measures ANOVA). (C (middle)) Percentage of nose pokes per quadrant 
separated by genotypes on day 12 (F(3,111) = 54.250, p < 0.001 in a two-way repeated 
measures ANOVA). (C (right)) Representative path traces on day 12 comparing WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice. All 
data were plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in 
a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc test. L, left; O, 
opposite; R, right; T, target. 
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Figure 3.12. Barnes Maze assessment of spatial memory at 15 months of age 
(A (left)) Primary latency to target hole on acquisition days 1-4 (the average values of 
four 3min trials per day are plotted) and test days 5 and 12 was measured for WT, 
TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 15 
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months (F(3,200) = 7.198, p < 0.001 in a two-way repeated measures ANOVA). (A 
(middle)) Primary latency to target hole on acquisition days 1-4 (the average values of 
four 3min trials per day are plotted) was measured for WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 , and TRPM2-KO-APPSWE/PSEN1∆E9 mice at 15 months 
(F(3,120) = 4.763, p < 0.05 in a two-way repeated measures ANOVA). (A (right)) Primary 
number of error to target hole on acquisition days 1-4 was measured for all genotypes at 
15 months. (B (left)) The number of nose pokes per quadrant were measured on test day 
5 in a 90s probe trial (F(9,120) = 4.344, p < 0.001 in a two-way repeated measures 
ANOVA). (B (right)) Percentage of nose pokes per quadrant separated by genotypes on 
day 5 (F(9,120) = 22.974, p < 0.001 in a two-way repeated measures ANOVA). (C (left)) 
The number of nose pokes per quadrant were measured on test day 12 in a 90s probe trial 
(F(9,120) = 2.006, p < 0.05 in a two-way repeated measures ANOVA). (C (right)) 
Percentage of nose pokes per quadrant separated by genotypes on day 12 (F(9,120) = 
14.823, p < 0.001 in a two-way repeated measures ANOVA). All data were plotted as 
Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-Sidak post 
hoc test; ***p < 0.001 in a Holm-Sidak post hoc test; ***’p = 0.001 in a Holm-Sidak post 
hoc test. L, left; O, opposite; R, right; T, target. 
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3.5 Morris water maze hidden-platform test 
 Spatial learning and memory were examined by Morris water maze (MWM) at 
twelve and fifteen months of age. In acquisition trials, mice were trained to locate a 
hidden platform placed in 1 of 4 quadrants in the maze. On day 5 of the probe trial, the 
platform was removed and mice were allowed to swim freely for 60 seconds. During this 
session, the amount of time spent in each of the quadrants was measured.  
No statistical differences in spatial memory were observed between WT, TRPM2-
KO, APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice at twelve 
months. There was no statistical difference between genotypes in terms of the latency to 
find the escape platform in the 4d training period, and all mice improved in the time it 
took to find the platform over training trials (Fig.3.13A; F(3,105) = 1.279, p = 0.297). No 
statistical difference between genotypes were observed in terms of distance required to 
find the platform (Fig.3.13B; F(3,105) = 1.636, p = 0.199). When spatial memory was 
investigated on probe trial day 5, the time WT, TRPM2-KO, APPSWE/PSEN1∆E9, and 
TRPM2-KO-APPSWE/PSEN1∆E9 mice spent investigating the target quadrant was 
significantly longer than all other quadrants (Fig.3.13C; F(3,105) = 39.134,  p<0.001; post 
hoc analysis show p<0.05, p<0.01, p=0.001, and p<0.001), indicating that all mice have 
learned the location of the target quadrant. Closer examination of representative path 
traces indicate that mice of all genotype are spending more time in the target quadrant 
and thus are learning, as well as remembering the locations of the platform (Fig.3.13D).  
At fifteen months, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice had a longer latency to find the escape platform in the 4d 
training period than control mice (Fig.3.14A; F(3,117) = 4.167, p < 0.05; post hoc analysis 
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show p<0.05 and p<0.01). In addition, the distance required for APPSWE/PSEN1∆E9  
and TRPM2-KO-APPSWE/PSEN1∆E9 mice to find the platform is significantly longer 
than controls (Fig.3.14B; F(3,117) = 9.619, p < 0.001; post hoc analysis show p<0.01 and 
p<0.001). When spatial memory was investigated on probe trial day 5, the time WT, 
TRPM2-KO, and TRPM2-KO-APPSWE/PSEN1∆E9 mice spent investigating the target 
quadrant was significantly longer than all other quadrants (Fig.3.14C; F(3,117) = 30.070, 
p<0.001; post hoc analysis show p<0.05, p<0.01, and p<0.001), suggesting that these 
mice remembered where the platform was located. However, APPSWE/PSEN1∆E9  
mice did not remember the location of the platform since these mice did not spend a 
significantly longer time investigating the target quadrant. Representative path traces 
further indicate that APPSWE/PSEN1∆E9 mice, contrary to WT, TRPM2-KO and 
TRPM2-KO-APPSWE/PSEN1∆E9 mice, do not remember the position of the platform 
and their swim paths are in a random pattern around the pool instead of only focusing on 
the target quadrant (Fig.3.14D). 
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Figure 3.13. MWM assessment of spatial memory at 12 months of age 
(A) WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9  
mice were subject to the MWM paradigm. Latency to find the platform on acquisition 
days 1-4 (the average of four 90s trials per day) is plotted (B) Total distance traveled to 
the platform on acquisition days 1-4 (the average of four 90s trials per day) is plotted (C) 
Percentage of time spent in each quadrant was measured on day 5 in a 60s probe trial 
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with the platform removed (F(3,105) = 39.134, p < 0.001 in a two-way repeated measures 
ANOVA). (D) Representative path traces on probe day 5 comparing WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 , and TRPM2-KO-APPSWE/PSEN1∆E9 mice. All data were 
plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-
Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc test; ***’p = 0.001 in a 
Holm-Sidak post hoc test. L, left; O, opposite; R, right; T, target. 
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Figure 3.14. MWM assessment of spatial memory at 15 months of age 
 
(A) WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9  
mice were subject to the MWM paradigm. Latency to find the platform on acquisition 
days 1-4 (the average of four 90s trials per day) is plotted (F(3,117) = 4.167, p < 0.05 in a 
two-way repeated measures ANOVA) (B) Total distance traveled to the platform on 
acquisition days 1-4 (the average of four 90s trials per day) is plotted (F(3,117) = 9.619, p < 
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0.001 in a two-way repeated measures ANOVA) (C) Percentage of time spent in each 
quadrant was measured on day 5 in a 60s probe trial with the platform removed (F(3,117) = 
16.466, p < 0.001 and F(3,117) = 30.070, p < 0.001 in a two-way repeated measures 
ANOVA). (D) Representative path traces on probe day 5 comparing WT, TRPM2-KO, 
APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice. All data were 
plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 0.01 in a Holm-
Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc test. L, left; O, opposite; R, 
right; T, target. 
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3.6 Morris water maze reversal learning 
Reversal learning is another set of experiment conducted one week after Morris 
water maze, again requiring 4d of acquisition (4 trials per day) and 1d of testing (1 trial 
per day). In this test however, the platform is relocated to the quadrant opposite of its 
former location. This reversal learning reveals whether or not animals can extinguish 
their previously learnt platform location and acquire a direct path to the new location 
(Faivre et al., 2012; Vorhees & Williams, 2006). In order to re-learn the location of this 
newly placed platform, cognitive flexibility needs to be present in these animals 
(Rosczyk, Sparkman, & Johnson, 2008). 
At 12 months of age, reversal learning experiments show no statistical difference 
between genotypes in terms of the latency to find the escape platform in the 4d training 
period, with all mice improved in the time it took to find the platform over training 
(Fig.3.15A; F(3,105) = 1.936, p = 0.142). No statistical difference between genotypes were 
observed in terms of distance required to find the platform (Fig.3.15B; F(3,105) = 2.891, p 
= 0.059). When spatial memory was investigated on probe trial day 5, the time WT, 
APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice spent investigating 
the target quadrant was significantly longer than all other quadrants (Fig.3.15C; F(3,105) = 
39.134,  p<0.001; post hoc analysis show p<0.05, p<0.01, and p<0.001). However, 
TRPM2-KO mice did not spend more time investigating the target quadrant. Instead, 
these mice spent similar amounts of time investigating all quadrants. This suggests that 
TRPM2-KO mice show impaired reversal learning. The representative path traces 
indicate that TRPM2-KO mice do not remember the position of the platform and their 
swim paths are in a random pattern around the pool instead of only focusing on the target 
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quadrant. On the other hand, WT, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice are spending more time in the target quadrant and thus are 
learning, as well as remembering the locations of the platform (Fig.3.15D). 
At 15 months of age, no statistical differences was observed between genotypes 
in terms of the latency to find the escape platform in the 4d training period, and all mice 
improved in the time it took to find the platform over training (Fig.3.16A; F(3,117) = 2.017, 
p=0.127). The distance required for APPSWE/PSEN1∆E9  and TRPM2-KO-
APPSWE/PSEN1∆E9 mice to find the platform is significantly longer than controls 
(Fig.3.16B; F(3,117) = 6.069, p < 0.01; post hoc analysis show p<0.05, p<0.01, and 
p<0.001). When spatial memory was investigated on probe trial day 5, the time WT and 
TRPM2-KO-APPSWE/PSEN1∆E9 mice spent investigating the target quadrant was 
significantly longer than all other quadrants (Fig.3.16C; F(3,117) = 29.914,  p<0.001; post 
hoc analysis show p<0.05, p<0.01, and p<0.001). Both TRPM2-KO and 
APPSWE/PSEN1∆E9 mice did not learn the location of the target quadrant since these 
mice did not spend a significantly longer time investigating the target quadrant, 
indicating that at this age both TRPM2-KO and APPSWE/PSEN1∆E9 mice show 
impaired reversal learning. The representative path traces indicate that both TRPM2-KO 
and APPSWE/PSEN1∆E9 mice show swim paths that are random around the pool 
instead of only focusing on the target quadrant (Fig.3.16D). 
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Figure 3.15. MWM assessment of reversal learning at 12 months of age 
 
(A) WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9  
mice were subject to reversal learning in MWM. Latency to find the platform on 
acquisition days 1-4 (the average of four 90s trials per day) is plotted (B) Total distance 
traveled to the platform on acquisition days 1-4 (the average of four 90s trials per day) is 
plotted (C) Percentage of time spent in each quadrant was measured on day 5 in a 60s 
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probe trial with the platform removed (F(3,105) = 31.318, p < 0.001 in a two-way repeated 
measures ANOVA). (D) Representative path traces on probe day 5 of reversal comparing 
WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9 mice. 
All data were plotted as Mean ± SEM. *p < 0.05 in a Holm-Sidak post hoc test; **p < 
0.01 in a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-Sidak post hoc test. L, left; 
O, opposite; R, right; T, target. 
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Figure 3.16. MWM assessment of reversal learning at 15 months of age 
 
(A) WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-APPSWE/PSEN1∆E9  
mice were subject to reversal learning in MWM. Latency to find the platform on 
acquisition days 1-4 (the average of four 90s trials per day) is plotted (B) Total distance 
traveled to the platform on acquisition days 1-4 (the average of four 90s trials per day) is 
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plotted (F(3,117) = 6.069, p < 0.01 in a two-way repeated measures ANOVA) (C) 
Percentage of time spent in each quadrant was measured on day 5 in a 60s probe trial 
with the platform removed (F(3,117) = 11.375, p < 0.001 and F(3,117) = 29.914, p < 0.001 in 
a two-way repeated measures ANOVA). (D) Representative path traces on probe day 5 of 
reversal comparing WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-KO-
APPSWE/PSEN1∆E9 mice. All data were plotted as Mean ± SEM. *p < 0.05 in a Holm-
Sidak post hoc test; **p < 0.01 in a Holm-Sidak post hoc test; ***p < 0.001 in a Holm-
Sidak post hoc test. L, left; O, opposite; R, right; T, target. 
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Section 4 
 
 
DISCUSSION 
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4.1 Summary of Key Findings 
 The main purpose of this thesis was to explore the relationship between TRPM2 
channels and cognitive impairment observed in an Alzheimer’s mouse model. I tested the 
hypothesis that genetic ablation of TRPM2 would prevent cognitive deficits in 
APPSWE/PSEN1∆E9 transgenic mice. Behavioral analysis suggested that: 
1) TRPM2 channels are important for reversal learning in aged mice, as TRPM2-KO 
mice at 12 month and older showed impaired performance in the MWM reversal 
learning task. 
2) Genetic ablation of TRPM2 improves cognition in APPSWE/PSEN1∆E9  
transgenic mice, as TRPM2-KO-APPSWE/PSEN1∆E9 mice showed improved 
performance on spatial memory, measured by BM and MWM tests and reversal 
learning. 
 
4.2 Open field locomotor activity test 
  The primary reason of conducting an open field locomotor activity test was to 
test whether mice were hyperactive, which is a common characteristic associated with 
several neurodegenerative disease models (Arendash et al., 2001). It is expected that mice 
will spend more time exploring their environment at the beginning because of the novel 
environment; however they will gradually decrease their exploration with time, since they 
will become familiar with the environment, otherwise known as habituation. This change 
in exploratory tendency was observed in our study; WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice at all ages showed a 
continued decrease in distance travelled during the two hour test period. Likewise, 
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Daenen et al. (2001) and Bolivar et al. (2000) also observed habituation in their cohort of 
male APPSWE/PSEN1∆E9 mice.  
Anxiety level in these rodents can also be recorded, by measuring the amount of 
time spent in the center of the open field activity chamber. Mice have a natural tendency 
to avoid open spaces by travelling along the walls of enclosures as a means of protection 
and easy escape (Lalonde et al., 2004). Therefore, the amount of time individuals spent in 
the center area of the open field test provides a measure of anxiety.  
No difference between WT, TRPM2-KO, APPSWE/PSEN1∆E9, and TRPM2-
KO-APPSWE/PSEN1∆E9 mice was observed in terms of total distance travelled and 
total time spent in the center of the chamber at 3, 6, and 9 months of age. However, after 
12 months of age, while no difference was seen between control mice (WT and TRPM-
KO), APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice showed 
significantly decreased horizontal activity. These mice also spent less time in the center 
of the chamber than controls. A number of studies in the literature have investigated 
locomotor activity in APPSWE/PSEN1∆E9 transgenic mice. Consistent with our results, 
no difference in locomotor activity was observed when APPSWE/PSEN1∆E9  
transgenic mice were compared to controls at different age points, such as at 4 months 
(Bonardi et al., 2011), 5-7 months (Lalonde et al., 2004), and 8 months (Park et al., 2010) 
of age.  
As mentioned above, no difference was seen between WT and TRPM2-KO mice 
while hypoactivity was observed in APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice. Because hypoactivity was only observed in Alzheimer’s 
mice and not in the control mice, regardless of the presence of TRPM2, we can conclude 
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that TRPM2 did not play a role in causing a decrease in horizontal activity in the 
Alzheimer’s mice. The behaviour of TRPM2-KO-APPSWE/PSEN1∆E9 mice was not 
improved when compared to the behaviour of APPSWE/PSEN1∆E9 mice, suggesting 
that knocking out TRPM2 did not interfere with locomotor activity in mice. 
 
4.3 Elevated plus maze 
The elevated plus maze is used to measure anxiety responses of rodents, where 
mice choose to either enter the open or closed arms. Mice were placed in the maze and 
their activities were measured for 5 minutes. This length of recording is based on an early 
study by Montgomery, (1955) who demonstrated that strongest avoidance behaviour for 
the open arms was seen in rats in the first 5 minutes after placement. If mice were left in 
the maze for a longer period of time, such as 10 or 15 minutes, these individuals would 
no longer experience fear and avoidance toward the open arms since they would 
habituate to the environment. 
The anxiety levels of WT, TRPM2-KO, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice did not differ at 3, 9, and 15 months of age. All mice 
performed equally well when placed on the elevated plus maze in terms of number of 
entries onto the open arm and the time spent on the open arms. To date, there have been 
controversial results regarding whether anxiety occurs or are absent in the 
APPSWE/PSEN1∆E9 transgenic mice. Consistent with these results, Arendash et al. 
(2001) studied the Tg2576 transgenic mice and found no difference between transgenic 
and control mice at 5-7 and 15-17 months of age in terms of performance in closed and 
open arm entries as well as time spent in open arms. On the other hand, there have been 
reports on APPSWE/PSEN1∆E9 mice which had results opposite of those found in this 
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current study. Lalonde et al. (2004) and Reiserer et al. (2007) found that 7 months old 
transgenic mice display reduced anxiety compared with wild type controls as measured 
by the elevated plus maze. Lalonde et al., (2004) also observed an increase in open arm 
entries as well as more time spent in the open arms in 7-month-old transgenic mice, 
suggesting that APPSWE/PSEN1∆E9 mice were less anxious than the control mice. The 
reason why results from our study and previous literatures did not match could be due to 
many factors such as temperature, noise levels, social interaction, the presence of 
enrichment and diet, which can impact anxiety levels and influence outcomes of the 
study. Light/dark cycle was found to be a significant factor in anxiety-like behaviour 
measured with the elevated plus maze (Clénet et al., 2006; Gomes et al., 2011). These 
scientists demonstrated that mice in the dark cycle spent more time in the open arm of the 
elevated plus maze, thus less anxious than mice in the light cycles. Elevated plus maze in 
our study was conducted when mice were in their light cycles which could be the reason 
why we are not seeing results consistent with others. In addition, housing conditions of 
mice has also been found to influence anxiety levels, as demonstrated by da Silva et al. 
(1996) where mice were either housed individually or in groups. They observed that mice 
housed individually had a reduced number of entries and spent less time in the open arms 
compared to mice housed in groups, coming to the conclusion that mice housed 
individually were more anxious than grouped mice, and vice versa. Although our mice 
were housed in groups and therefore should be less anxious, we did not see this result in 
mice at 3, 9, and 15 months of age.  
At 6 months however, TRPM2-KO-APPSWE/PSEN1∆E9 mice spent 
significantly longer time in the open arms than the control mice, suggesting that these 
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mice may be less anxious than WT, TRPM2-KO and APPSWE/PSEN1∆E9 mice. In 
contrast, at 12 months of age, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice visited the open arms significantly fewer times than control 
mice, suggesting that these mice are more anxious than controls. Consistent with this, 
Filali, Lalonde, and Rivest (2011) found that APPSWE/PSEN1∆E9 transgenic mice spent 
more time in the closed arms and less time in the open arms and therefore were more 
anxious than controls. Overall, our results suggest that APPSWE/PSEN1∆E9 and 
TRPM2-KO-APPSWE/PSEN1∆E9 mice do not differ in anxiety levels, in terms of 
hyperactivity when compared to control mice. Because there were no consistent changes 
in anxiety in all mice, this suggests that elimination of TRPM2 does not affect anxiety 
levels in the elevated plus maze. 
 
4.4 Object recognition 
The object recognition test, which is based on the ability of mice to discriminate 
novel objects, was used to evaluate the performance of WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 , and TRPM2-KO-APPSWE/PSEN1∆E9 mice. Mice have a 
natural tendency to explore a novel object, which can reflect the individual’s use of 
discriminatory short- or long-term memory (Otalora et al., 2012; Prado et al., 2006). 
Short-term memory would involve a test being given to the mice shortly (a few hours) 
after training, whereas long-term memory involves a test being given 24 hours after 
training. Our study tested the long-term memory of WT, TRPM2-KO, 
APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9 mice.  
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Our results demonstrated no genotype difference in terms of the percentage of 
time spent exploring the familiar and novel objects. All mice preferred to explore the 
novel object on testing day at both 9 and 12 months of age. A number of researchers have 
studied the APPSWE/PSEN1∆E9 transgenic mouse model using this test and 
controversial results have been found regarding the age at which discriminatory memory 
deficits occur. Consistent with our results, Bonardi et al. (2011) and Jardanhazi-Kurutz et 
al. (2010) found no memory deficit in the same APPSWE/PSEN1∆E9 transgenic mice at 
earlier ages (4 and 6 months). However, findings from Donkin et al. (2010) and Yoshiike 
et al. (2008) on the APPSWE/PSEN1∆E9 mice were contradictory to our results since 
both cohorts of mice demonstrated a severe object recognition memory deficit in 
APPSWE/PSEN1∆E9 mice at 9-13 months of age. Overall, our results suggest that 
discriminatory memory of APPSWE/PSEN1∆E9 and TRPM2-KO-APPSWE/PSEN1∆E9  
mice do not differ from control mice. Because all mice learnt well in this test, this 
allowed me to demonstrate that knocking out TRPM2 does not affect mice’s 
discriminatory memory in object recognition. 
 
4.5 Barnes maze 
  One of the methods to assess spatial learning and memory in mice is with the 
Barnes maze, consisting of an open, exposed platform elevated off the ground with an 
escape box located somewhere along the perimeter of the platform.  
At 3, 6, and 9 months of age, no cognitive impairment was present in 
APPSWE/PSEN1∆E9 mice since all mice remembered the location of the escape box 
with the guidance of visual cues surrounding the maze. At 12 months however, when 
 81 
 
testing memory retention on day 5, APPSWE/PSEN1∆E9 mice visited the target hole 
location significantly less than control indicating spatial memory deficit in these mice. 
Day 12 of the probe trial also indicated a spatial memory deficit in APPSWE/PSEN1∆E9  
mice. TRPM2-KO-APPSWE/PSEN1∆E9 mice had improved performance in the BM on 
both test days 5 and 12. Therefore, elimination of TRPM2 alleviates spatial memory 
deficit seen in mice expressing the APPSWE/PSEN1∆E9 transgene. In addition, 
APPSWE/PSEN1∆E9 mice at 15 months of age also showed spatial memory deficit as 
measured on probe day 5 and 12, as well as an improvement in performance when the 
TRPM2 gene is eliminated. These results suggest that spatial memory deficits, as 
measured by BM, only occur in aged APPSWE/PSEN1∆E9 mice, at 12 and 15 months of 
age. Our data also support the notion that elimination of TRPM2 can reverse or prevent 
these alterations in spatial memory. 
APPSWE/PSEN1∆E9 transgenic mice have been shown to exhibit age-dependent 
spatial learning and memory impairment in the Barnes maze. To date, there have been 
controversial results regarding whether spatial memory deficit occurs at an earlier age or 
a later age. For instance, Reiserer et al. (2007) has demonstrated that 6-7 months old 
APPSWE/PSEN1∆E9 mice shows cognitive impairment in BM. However, O’Leary & 
Brown, (2009) have shown results consistent with our current results; spatial memory 
deficit only occurs in aged mice. O’Leary & Brown, (2009) assessed spatial memory of 
APPSWE/PSEN1∆E9 transgenic mice at 16 months of age using the Barnes maze and 
observed that transgenic mice took a longer time to locate the target hole than WT mice, 
as well as made more errors during acquisition trials. The above observations therefore 
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demonstrate the presence of spatial learning and memory impairment in 
APPSWE/PSEN1∆E9 mice as measured by Barnes maze.  
 
4.6 Morris water maze hidden-platform test 
 Morris water maze (MWM) is a test used for spatial learning and memory 
(Vorhees & Williams, 2006). Since mice have a natural fear of water, this test uses this 
fear as a motivation for these individuals to find the hidden platform with the aid of 
visual cues. Similarly to the Barnes maze, WT mice are expected to utilize spatial 
learning and memory in order to locate the hidden platform. Because of the potential 
spatial memory deficits we observed in the BM, we decided to determine if a second task 
would allow us to confirm these results. 
At 12 months of age, all mice learned and retained the memory of the location of 
the target platform, as seen by the large amount of time spent in the target quadrant. 
Opposite from our findings, Zhang et al. (2011) demonstrated the presence of spatial 
memory deficit in the APPSWE/PSEN1∆E9 mice at 12 months of age.  
At 15 months of age, APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice took a longer period of time to find the target location 
(Fig.3.14A) as well as travelled a longer distance (Fig.3.14B) than control mice but they 
learnt the test. It is interesting to note that, likely, WT and TRPM-KO mice remember 
that they have done this experiment multiple times and already in the first day of training 
they promptly find the platform, while APPSWE/PSEN1∆E9 and TRPM2-KO-
APPSWE/PSEN1∆E9 mice behave as if they were doing the test for the first time. 
However, we observe a spatial memory deficit in APPSWE/PSEN1∆E9 mice, since these 
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mice do not remember the location of the target platform on the probe trial. TRPM2-KO-
APPSWE/PSEN1∆E9 mice were found to have  improved performance in this test since 
they remember the location of the target platform and therefore spent more time in that 
quadrant. This demonstrates that knocking out the expression of TRPM2 led to an 
improved cognitive function in APPSWE/PSEN1∆E9 mice.  
APPSWE/PSEN1∆E9 transgenic mice have been shown to exhibit age-dependent 
spatial learning and memory impairment in the MWM. To date, just like BM, there have 
been controversial results regarding whether spatial memory deficit occurs at an earlier 
age or a later age in the MWM. Some studies have observed a lack of spatial memory 
impairment in APPSWE/PSEN1∆E9  mice at 6 months (Holcomb et al., 1999; 
Minkeviciene et al., 2008; Savonenko et al., 2005) and 9 months (Holcomb et al., 1999) 
of age, while memory deficit have been found to present itself at 8-12 (Butovsky et al., 
2006; Cao et al., 2007; Lalonde et al., 2004; Minkeviciene et al., 2008; Oksman et al., 
2006), 12-13 months of age (Malm et al., 2011; Zhang et al., 2011), 14 months of age 
(Liu et al., 2003), and 16-18 months of age (Malm et al., 2007; Minkeviciene et al., 2008; 
Savonenko et al., 2005). The results from our study are consistent with numerous reports 
that indicate APPSWE/PSEN1∆E9 mice show spatial learning and memory deficits at 12 
and 15 months of age. Overall, our results demonstrated that elimination of TRPM2 
allows for improved performance compared to APPSWE/PSEN1∆E9 mice in MWM. 
 
4.7 Morris water maze reversal learning 
MWM reversal, or reversal learning, tests an animal’s ability to extinguish their 
memory of the previously learnt platform position and essentially to “re-learn” the new 
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platform position (Vorhees & Williams, 2010). This test was conducted a week after the 
original MWM, using the same materials but a slight modification to the methodology, 
with the location of the hidden platform now being placed in the opposite quadrant of 
where it used to be. In order to re-learn the location of this newly placed platform, 
cognitive flexibility needs to be present in these animals. 
An unexpected result arose when observing MWM reversal learning. At 12 
months of age, cognitive flexibility was present in WT, APPSWE/PSEN1∆E9 and 
TRPM2-KO-APPSWE/PSEN1∆E9 mice since they found the new location of the hidden 
platform quickly and accurately. However, TRPM2-KO mice did not find the new hidden 
platform location and therefore presented a deficit in cognitive flexibility. At 15 months 
of age, WT and TRPM2-KO-APPSWE/PSEN1∆E9  mice were observed to remember 
the new location of the platform while TRPM2-KO and APPSWE/PSEN1∆E9 mice did 
not; indicating a deficit in cognitive flexibility in these mice as well as a possible 
impairment in LTP in the APPSWE/PSEN1∆E9 mice since these mice had trouble 
remembering the new location of the platform. The fact that we observe cognitive 
flexibility deficits in mice with elimination of TRPM2 (TRPM2-KO) at 12 months of age 
but no deficits in Alzheimer’s mice, were interesting yet puzzling. Moreover, 15 months 
results showed that mice with elimination of TRPM2 (TRPM-KO) as well as 
APPSWE/PSEN1∆E9 mice had a deficit in cognitive flexibility, again suggesting a 
possible LTP impairment in these mice. However, TRPM2-KO-APPSWE/PSEN1∆E9 
mice had no deficit in cognitive flexibility at 12 and 15 months of age, instead they had 
normal performance at both age points, suggesting that at both time points, the 
elimination of TRPM2 channels may be beneficial and may rescue the LTP impairment. 
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There is no explanation for our results at this time; future in vivo research should further 
investigate TRPM2-KO mice and reversal learning as well as the role that TRPM2 has in 
these behaviour tests. For example, because there are numerous mouse models of AD as 
noted in the introduction, longitudinal research could be conducted in those mouse 
models to investigate whether or not knocking out TRPM2 played a role in performance. 
TRPM2-KO mice and reversal learning can also be further investigated using other 
mouse models of AD to see if the same results are obtained compared to the unexpected 
results we saw in reversal learning. These results observed in the MWM reversal tests in 
our study could be correlated to an in vitro experiment conducted by Xie et al., (2011), 
described below. 
TRPM2 channels are highly expressed in the CNS and have previously been 
found to be expressed in the CA1 pyramidal neurons in the hippocampus (Olah et al., 
2009). Based on this finding, an in vitro study by Xie et al., (2011) used hippocampal 
cultures and slices from TRPM2 knockout mice and demonstrated that a loss of TRPM2 
channels selectively impairs NMDAR-dependent LTD while sparing LTP. LTD is an 
activity-dependent reduction in the efficacy of excitatory synaptic transmission while 
LTP is the opposite; an enhancement in the efficacy of transmission. In order to further 
explore the loss of NMDAR-dependent LTD in TRPM2 knockout mice, these scientists 
examined the activity of GSK-3β (glycogen synthase kinase-3β), which has been widely 
implicated in AD and is required in the formation of this LTD (Jo et al., 2011). Genetic 
deletion of TRPM2 was to be associated with decreased GSK-3β activity. However, it 
was noted that a rescue of LTD was observed in TRPM2 knockout mice when GSK-3β 
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activity was restored. Therefore, TRPM2 channels have been demonstrated to play a key 
role in hippocampal synaptic plasticity. 
Recall that Aβ plaques are the main pathological hallmark of AD (Cvetkovic-
dozic et al., 2001; Yankner, Lu, & Loerch, 2008) and that Aβ40 and Aβ42 are the two 
most common species of Aβ (Oddo et al., 2003; Selkoe, 2008). An increased production 
of oligomeric Aβ42 is one of the triggers of FAD (Savonenko et al., 2005), resulting in 
the accumulation of large senile plaque in the hippocampus, cortex and subcortical nuclei 
(Duyckaerts et al., 2008). Oligomeric Aβ42 has been shown by numerous studies to 
inhibit LTP, important in memory formation (Shankar et al., 2008; Walsh et al., 2002) as 
well as increase LTD, contributing in memory loss (Hsieh et al., 2006; Li et al., 2009; 
Shankar et al., 2008).   
Given that the loss of TRPM2 expression leads to deficits in LTD induction, an 
increase in TRPM2 channel function, for example as a result of oxidative stress, may 
favor LTD. Accordingly, we propose that the increased LTD associated with AD is 
partially contributed by augmented TRPM2 function, via Aβ42 initiated oxidative stress. 
And therefore, it can be concluded that a loss of TRPM2 channel activity may play a 
beneficial role in learning and memory in AD. 
 
4.8 Future directions  
 As noted in the introduction, soluble oligomers have been found by numerous 
studies to mediate neurotoxicity by inducing oxidative stress in the brain which promote 
TRPM2 activation, leading to a disruption in Ca2+ homeostasis and a toxic influx of  
Ca2+, ultimately inducing cell death (Goedert & Spillantini, 2006; Mattson, 2007; 
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Takahashi et al., 2011). An improvement in memory in the TRPM2-KO-
APPSWE/PSEN1∆E9 mice has been observed in our study and therefore knocking out 
TRPM2 has been found to be protective. Cognition was found to be mildly impaired in 
TRPM2-KO mice, as shown by impaired reversal learning. Future in vitro research could 
explore Aβ load in these TRPM2-KO individuals and see whether or not the load has 
decreased in these individuals since there was an improvement in behaviour. Presently, 
there are no specific antagonists of TRPM2. However, a number of pharmacological 
agents are able to inhibit the channel, although only non-selectively. These agents include 
flufenamic acid, econazole, clotrimazole, and N-(p-amycinnamoyl) (Eisfeld & Luckhoff, 
2007; Olah et al., 2009). Thus, these potential TRPM2 antagonists should also be 
investigated in order to examine whether TRPM2 represents a target for the treatment of 
AD. Given our findings, we predict that a TRPM2 antagonist could potentially be 
effective in treating AD. 
 My study focuses on mice with TRPM2 absent from birth, which is different than 
humans who develop AD with age. To test the effectiveness of a TRPM2 blocker in 
patients already suffering the symptoms, longitudinal studies in which treatment is 
initiated at various time points (e.g. 3, 6, 9 months etc.) should be performed on mouse 
models of AD. In addition, biomarkers of AD may soon allow us to identify humans at 
risk of developing AD; treatment in these patients with a TRPM2 blocker could be 
considered.  
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4.9 Overall conclusions 
Although the precise mechanism through which Aβ causes AD pathogenesis is 
not known at present, this mechanism can be speculated taking into consideration the 
large amount of research on this topic. To date, it is known that the accumulation of Aβ is 
the main pathological hallmarks of AD, and that Aβ induces oxidative stress and a loss of 
Ca2+ homeostasis in the brain. According to the amyloid cascade hypothesis, the 
accumulation of soluble Aβ peptides causes progressive synaptic and neuritic injury by 
reducing glutamatergic synaptic transmission strength and plasticity (Hardy, & Selkoe, 
2002; Palop, & Mucke, 2010). Similarly, a loss of Ca2+ homeostasis is known to disrupt 
the structure and function of synapses, impair synaptic plasticity, and ultimately cause 
cell death. Although the precise mechanisms through which oxidative stress causes a loss 
of Ca2+ homeostasis is not known, we do know that oxidative stress promotes the 
activation of TRPM2 channels and that this activation causes a toxic influx of Ca2+ and 
ultimately induce cell death (Takahashi et al., 2011). Collectively, these findings led us to 
consider TRPM2 channels as a likely contributor to the neurotoxic cascades initiated by 
elevated Aβ levels. 
This thesis was the first to explore the relationship between TRPM2 and cognitive 
deficits associated with a well characterized mouse model of Alzheimer’s disease. Our 
results suggest that knocking out the TRPM2 transgene improves the spatial learning and 
memory abilities of the APPSWE/PSEN1∆E9 double transgenic mice, suggesting that 
TRPM2 might represent a potential target for the treatment of AD. 
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